Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (323)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (10)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (655)
  2. Center for Hematologic Malignancies (655)
  3. Department of Medicine (655)
  4. Hematologic Malignancies, Division of (655)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (118)
  3. Jae Park (81)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Blood Advances (27)
  4. Leukemia Research (27)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (25)

More Publications

Publishers
  1. American Society of Hematology (301)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (655)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Lineage deconvolution using chromatin accessibility and DNA methylation shows a spectrum of lineage characteristics and differentiation states across acute leukemias
    Meeting Abstract

    Glass, J. L.; Palia, A. J.; Garrett-Bakelman, F. E.; Koche, R.; Levine, R. L.; Tallman, M. S.; Dillon, R. J.; Grimwade, D.; Ferrando, A. A.; Valk, P. J. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Molecular profiling in extramedullary acute myeloid leukemia reveals distinct subgroups defined by mutations in KIT and RUNX1
    Meeting Abstract

    Goldberg, A. D.; Farnoud, N.; Goldberger, C.; Patel, M.; Famulare, C.; Medina, J.; Rampal, R. K.; Levine, R. L.; Berman, E.; Zhang, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia
    Meeting Abstract

    Goldberg, A. D.; Tallman, M. S.; Solh, M. M.; Ungar, D.; Rizzieri, D. A.; Walter, R. B.; Spira, A. I.; Chung, K. Y.; Stock, W.; He, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prospective study of acute myeloid leukemia (AML) clinical epidemiology and cytogenetic risk group in older adults in the ECOG-ACRIN E2906 clinical trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) study
    Meeting Abstract

    Foran, J. M.; Zhang, Y.; Heckman, M.; Luger, S.; Hulshizer, C.; Vargas, E.; Litzow, M. R.; Altman, J. K.; Pratz, K.; Mattison, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations
    Meeting Abstract

    Durham, B. H.; Getta, B.; Dietrich, S.; Taylor, J.; Won, H.; Bogenberger, J. M.; Scott, S. N.; Kim, E.; Chung, Y. R.; Chung, S. S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Widespread use of measurable residual disease in acute myeloid leukemia practice
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Estey, E. H.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • Myeloid malignancies following luminal gastrointestinal cancer: High incidence of deletion 5q and DNTM3A mutations
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Klimek, V. M.; Saltz, L. B.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study
    Meeting Abstract

    Döhner, K.; Thiede, C.; Larson, R. A.; Prior, T. W.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lo Coco, F.; Ottone, T.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)
    Meeting Abstract

    Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; more...
    Blood (2017)

    Fulltext@MSK | Save